FAKTOR OPTIONSSCHEIN - DEXCOM Stock

DE000PE8DEX7

Delayed Deutsche Boerse AG 08:50:37 2024-06-27 EDT
1.7 ^EUR	-0.58%

Current month	-44.12%
1 month	-77.32%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart DEXCOM, INC.

Latest news about DEXCOM, INC.

Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.	08:31am	BU
Wall Street: up, on the edge, despite rates	06-26	CF
Out with AI, in with defensive stocks	06-25
Glucotrack Announces the Appointment of Andy Balo to Board of Directors	06-20	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-27	1.7	-0.58%
24-06-26	1.71	+20.42%
24-06-25	1.42	0.00%
24-06-24	1.42	-41.80%
24-06-21	2.44	+1.67%

Delayed Quote Deutsche Boerse AG

Last update June 27, 2024 at 08:50 am

More quotes

Static data

Product type	Produits Exotiques
Buy / Sell	CALL
Underlying	DEXCOM, INC.
Issuer	BNP Paribas
WKN	PE8DEX
ISIN	DE000PE8DEX7
Date issued	2023-08-28
Strike	113.5 $
Maturity	Unlimited
Parity	1 : 1
Emission price	100 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	144.4 €
Lowest since issue	1.31 €
Spread	0.16 €
Spread %	8.60%

Company Profile

DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 72.5% of net sales.

Sector

More about the company

Ratings for DexCom, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: DexCom, Inc.

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

113.5 USD

Average target price

150.3 USD

Spread / Average Target

+32.45%

Consensus